Sensei Biotherapeutics (SNSE) Financials

$25.96

$-10.21 (-28.23%)

As on 17-Jul-2026 09:30EDT

Market cap

$19 Mln

Revenue (TTM)

$-5 Mln

P/E Ratio

--

P/B Ratio

4.9

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	-4.85	--	--	--	--	--
Cost of Revenue	132.89	--	0.55	0.57	1.81	0.69
Gross Profit	-132.89	--	-0.55	-0.57	-1.81	-0.69
Operating Expenses	65.86	22.29	31.11	36.49	50.19	36.80
Operating Profit (EBIT)	-198.82	-22.29	-31.66	-37.06	-50.19	-37.48
Other Income	--	--	--	--	--	--
Profit before Tax	-195.53	-21.09	-30.16	-34.10	-48.59	-36.79
Provision for Tax	--	--	--	0.10	0.22	0.67
Profit after Tax (Net Income)	-195.53	-21.09	-30.16	-34.10	-48.81	-36.79
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-48.59	-36.79

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	172.96	18.59	38.39	64.90	103.41	146.51
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.00	0.06	1.53	3.84	5.90	1.82
Current Liabilities	9.58	4.25	5.45	5.64	9.07	4.89
Total Liabilities	192.12	22.90	45.36	74.37	118.38	153.23

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.65	1.40	3.43	7.12	9.79	4.68
Current Assets	188.66	21.51	41.93	67.25	108.59	148.54
Total Assets	198.89	22.90	45.36	74.37	118.38	153.23
Total Debt*	0.59	1.51	3.85	6.21	8.03	2.35
Net Current Assets	179.08	17.26	36.48	61.61	99.52	143.65

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-20.45	-24.67	-32.02	-39.03	-30.26
Cash Flow from Investing Activities	--	19.77	22.44	38.41	49.95	-143.12
Cash from Financing Activities	--	-0.65	-0.79	-11.17	-0.29	163.94
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-141.65	-16.72	-1.20	-1.36	-1.59	-1.20
Cash EPS ($)	--	-16.61	-1.15	-1.31	-1.54	-1.18
Adjusted Book Value ($)	--	14.75	1.53	2.59	3.36	4.79
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-16.22	-0.98	-1.28	-1.27	-0.99
Free Cash Flow per Share ($)	--	-16.23	-0.99	-1.29	-1.28	-1.06

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-67.65	-53.22	-37.36	-37.50	-44.48
ROE (%)	-204.15	-74.01	-58.40	-40.52	-39.06	-45.31
ROA (%)	-166.73	-61.78	-50.37	-35.38	-35.94	-42.13
EBIT Margin (%)	4,030.51	--	--	--	--	--
Net Margin (%)	4,030.69	--	--	--	--	--
Cash Profit Margin (%)	0.03	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-991.73	--	--	--	--	--
EBIT Growth (%)	-630.59	29.98	18.88	26.15	-38.93	-96.21
Net Profit Growth (%)	-628.96	30.08	11.57	30.13	-32.65	-83.05
EPS Growth (%)	-2,860.65	-12.96	0.12	0.14	-0.32	-0.13
Book Value Growth (%)	41.49	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.64	-0.41	-0.51	-0.94	-4.82
Price / Book Value	4.86	0.72	0.32	0.27	0.44	1.21
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.36	0.30	0.85	1.26	1.09	-0.91
Close Price ($)	22.87	10.67	9.80	13.84	29.80	116.00
High Price ($)	36.76	18.35	38.80	38.52	123.40	530.00
Low Price ($)	6.33	5.00	7.68	10.20	26.00	94.00
Market Cap ($ Cr)	18.59	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.08	0.10	0.10	0.08	0.02
Short term debt to equity ratio	0.00	0.08	0.06	0.04	0.02	0.00
Current Ratio	19.69	5.06	7.70	11.92	11.98	30.38
Quick Ratio	19.69	--	--	--	--	--
Interest Coverage	-21,724.44	-657.91	-334.08	-257.39	-229.17	-53.92

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	-0.04	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	642.34	1,972.41	699.89	1,689.75
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.